Skip to main content
SpringerLink
Log in

Treatment

  • Chapter
  • First Online:
Book cover Clinician's Guide to Mycosis Fungoides

Abstract

Treatment of mycosis fungoides (MF) depends on the stage of the disease. Treatment options for MF include skin-directed therapies, systemic therapies, and combination therapies. Skin-directed therapies are generally used in treating the earlier stages (I–IIA) of MF and include the following: topical agents, phototherapy, and electron beam therapy. Systemic therapies are used in advanced or refractory stages of MF. Combination therapies are those that combine skin-directed therapies and systemic therapies, or various types of systemic therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Olsen E, Whittaker S, Kim Y, Duvic M, Prince H, Lessin S, et al. International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598–607.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Freiman A, Sasseville D. Treatment of mycosis fungoides: overview. J Cutan Med Surg. 2006;10(5):228–33.

    Article  PubMed  Google Scholar 

  3. Galper SL, Smith BD, Wilson LD. Diagnosis and management of mycosis fungoides. Oncology. 2010;24(6):491.

    PubMed  Google Scholar 

  4. Liu DY, Shaath T, Rajpara AN, Hanson C, Fraga G, Fischer R, et al. Safe and efficacious use of intralesional steroids for the treatment of focally resistant mycosis fungoides. J Drugs Dermatol. 2015;14(5):466–71.

    CAS  PubMed  Google Scholar 

  5. Van Scott EJ, Kalmanson JD. Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance. Cancer. 1973;32(1):18–30.

    Article  PubMed  Google Scholar 

  6. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139(2):165–73.

    CAS  PubMed  Google Scholar 

  7. Talpur R, Venkatarajan S, Duvic M. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. Expert Rev Clin Pharmacol. 2014;7(5):591–7.

    Article  CAS  PubMed  Google Scholar 

  8. Zackheim HS. Topical carmustine (BCNU) for patch/plaque mycosis fungoides. Seminars in dermatology. 1994;13(3):202–6.

    Google Scholar 

  9. Zackheim HS, Epstein EH, Crain WR. Topical carmustine (BCNU) for cutaneous t cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol. 1990;22(5):802–10.

    Article  CAS  PubMed  Google Scholar 

  10. Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther. 2003;16(4):283–7.

    Article  PubMed  Google Scholar 

  11. Gunderson LL, Tepper JE. Clinical radiation oncology. Philadelphia: Elsevier Health Sciences; 2015.

    Google Scholar 

  12. Kim EJ, Lin J, Junkins-Hopkins JM, Vittorio CC, Rook AH. Mycosis fungoides and sezary syndrome: an update. Curr Oncol Rep. 2006;8(5):376–86.

    Article  PubMed  Google Scholar 

  13. Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801–15.

    Article  PubMed  Google Scholar 

  14. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138(3):325–32.

    Article  CAS  PubMed  Google Scholar 

  15. Trautinger F. Phototherapy of mycosis fungoides. Photodermatol Photoimmunol Photomed. 2011;27(2):68–74.

    Article  PubMed  Google Scholar 

  16. Herrmann JJ, Roenigk HH, Hurria A, Kuzel TM, Samuelson E, Rademaker AW, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol. 1995;33(2):234–42.

    Article  CAS  PubMed  Google Scholar 

  17. Rupoli S, Goteri G, Pulini S, Filosa A, Tassetti A, Offidani M, et al. Long-term experience with low-dose interferon-α and PUVA in the management of early mycosis fungoides. Eur J Haematol. 2005;75(2):136–45.

    Article  CAS  PubMed  Google Scholar 

  18. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin’s lymphoma version 3 (2016), Vol. 3 Fort Washington: National Comprehensive Care Network; 2016. p. 105–18.

    Google Scholar 

  19. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol. 1996;132(11):1309–13.

    Article  CAS  PubMed  Google Scholar 

  20. Deeths MJ, Chapman JT, Dellavalle RP, Zeng C, Aeling JL. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005;52(2):275–80.

    Article  PubMed  Google Scholar 

  21. Martínez-González MC, Verea-Hernando MM, Yebra-Pimentel MT, Del Pozo J, Mazaira M, Fonseca E. Imiquimod in mycosis fungoides. Eur J Dermatol. 2008;18(2):148–52.

    PubMed  Google Scholar 

  22. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581–93.

    CAS  PubMed  Google Scholar 

  23. Hall JC, Hall BJ. Cutaneous lymphoma: diagnosis and treatment. Shelton: PMPH; 2012.

    Google Scholar 

  24. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9(5):1089–107.

    CAS  PubMed  Google Scholar 

  25. Spaccarelli N, Rook AH. The use of interferons in the treatment of cutaneous T-cell lymphoma. Dermatol Clin. 2015;33(4):731–45.

    Article  CAS  PubMed  Google Scholar 

  26. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Whittaker SJ, Demierre M-F, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485–91.

    Article  CAS  PubMed  Google Scholar 

  28. Tani M, Fina M, Alinari L, Stefoni V, Baccarani M, Zinzani P. Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. Haematologica. 2005;90(9):1283–4.

    CAS  PubMed  Google Scholar 

  29. Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(29):4492–9.

    Article  PubMed  Google Scholar 

  30. Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;32(29):3347–8.

    Article  PubMed  Google Scholar 

  31. Mao X, Orchard G, Mitchell TJ, Oyama N, Russell‐Jones R, Vermeer MH, et al. A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS. J Cutan Pathol. 2008;35(10):899–910.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Health Management, New York Medical College, Valhalla, New York, USA

    Pooya Khan Mohammad Beigi

  2. University of British Columbia, Vancouver, British Columbia, Canada

    Pooya Khan Mohammad Beigi

  3. Misdiagnosis Association, Seattle, Washington, USA

    Pooya Khan Mohammad Beigi

Authors
  1. Pooya Khan Mohammad Beigi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Khan Mohammad Beigi, P. (2017). Treatment. In: Clinician's Guide to Mycosis Fungoides. Springer, Cham. https://doi.org/10.1007/978-3-319-47907-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-47907-1_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-47906-4

  • Online ISBN: 978-3-319-47907-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation